Results 51 to 60 of about 5,707 (185)
Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.ABSTRACT Pituitary adenomas (PAs) are common intracranial tumours, and invasiveness in nonfunctioning invasive pituitary adenomas (NIPAs) predicts poor prognosis. The molecular mechanisms driving this phenotype remain unclear. This study explored the role of nuclear receptor subfamily 3 group C member 1 (NR3C1) in NIPA invasiveness and its regulation ...
Xiaoping Wang +6 more
wiley +1 more source
Parathormone-Related Peptide Is Not Associated with Bone Mineral Density in Eugonadal Prolactinoma
Endocrinology Research and Practice, 2023 Objective: One of many theories for the cause of osteoporosis in prolactinoma is the increased level of the parathyroid hormone-related peptide. We aimed to assess the parathyroid hormone-related pep- tide levels and its potential effects on bone mineral
Arzu Okyar Baş +2 more
doaj
Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.Abstract The chemokine network in the microenvironment of pituitary neuroendocrine tumours (PitNETs) may modulate tumour biology, aggressiveness, and treatment responses. We aimed to study the role of various chemokines and chemokine receptors in defining PitNET phenotype and clinical outcomes.
Ana Luísa Silva +13 more
wiley +1 more source
Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion
Open Chemistry, 2018 Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy.
Liu Qian +5 more
doaj +1 more source
F1000Research, 2018 Background: Pituitary disorders spectrum includes a wide variety of diseases.This study aimed at a comprehensive description of such disorders for patients from Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) in Basrah (Southern Iraq)
Abbas Ali Mansour +11 more
doaj +1 more source
Aggressive and Malignant Prolactinomas [PDF]
Neuroendocrinology, 2019 Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and ...
Olarescu, Nicoleta Cristina +7 more
openaire +6 more sources
CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.Loss of INPP5A in PitNETs disrupts IP3 clearance and drives aberrant PI3K/Akt activation. PKA‐dependent phosphorylation stabilizes MBD2 via 14‐3‐3σ, sustaining transcriptional silencing of INPP5A. MBD2 inhibition sensitizes tumors to standard treatments and limits PitNET growth.
Qian Jiang +12 more
wiley +1 more source
Equine Veterinary Education, Volume 38, Issue 3, Page e170-e179, March 2026.Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess +5 more
wiley +1 more source
Journal of Neuroendocrinology, Volume 38, Issue 3, March 2026.Abstract Nonfunctioning pituitary adenomas (NFPAs) are common intracranial tumors that, despite being histologically benign, can exhibit invasive growth, as well as postoperative tumor progression. Surgical resection is the primary treatment of choice; however, residual tumor tissue is frequently observed, with between 30% and 50% of these cases ...
Thomas Skoglund +5 more
wiley +1 more source